ATE223486T1 - Bmp-9 zusammensetzungen - Google Patents

Bmp-9 zusammensetzungen

Info

Publication number
ATE223486T1
ATE223486T1 AT95923706T AT95923706T ATE223486T1 AT E223486 T1 ATE223486 T1 AT E223486T1 AT 95923706 T AT95923706 T AT 95923706T AT 95923706 T AT95923706 T AT 95923706T AT E223486 T1 ATE223486 T1 AT E223486T1
Authority
AT
Austria
Prior art keywords
bmp
compositions
proteins
bone
processes
Prior art date
Application number
AT95923706T
Other languages
English (en)
Inventor
Vicki A Rosen
John M Wozney
Anthony J Celeste
Scott R Thies
Jeffrey J Song
Original Assignee
Inst Genetics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Genetics Llc filed Critical Inst Genetics Llc
Application granted granted Critical
Publication of ATE223486T1 publication Critical patent/ATE223486T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/84—Bones; tendons; teeth; cartilage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dental Preparations (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
AT95923706T 1994-06-06 1995-06-05 Bmp-9 zusammensetzungen ATE223486T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/254,353 US6287816B1 (en) 1991-06-25 1994-06-06 BMP-9 compositions
PCT/US1995/007084 WO1995033830A1 (en) 1994-06-06 1995-06-05 Bmp-9 compositions

Publications (1)

Publication Number Publication Date
ATE223486T1 true ATE223486T1 (de) 2002-09-15

Family

ID=22963968

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95923706T ATE223486T1 (de) 1994-06-06 1995-06-05 Bmp-9 zusammensetzungen

Country Status (8)

Country Link
US (2) US6287816B1 (de)
EP (2) EP1230930A3 (de)
JP (1) JP3706133B2 (de)
KR (1) KR100255417B1 (de)
AT (1) ATE223486T1 (de)
AU (1) AU709869B2 (de)
DE (1) DE69528058T2 (de)
WO (1) WO1995033830A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) * 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US5656593A (en) * 1991-03-11 1997-08-12 Creative Biomolecules, Inc. Morphogen induced periodontal tissue regeneration
US20080139474A1 (en) * 1991-11-04 2008-06-12 David Israel Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
JP3504263B2 (ja) * 1991-11-04 2004-03-08 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー 組み換え型骨形態形成蛋白ヘテロダイマー、組成物および使用法
US6291206B1 (en) * 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US5902785A (en) * 1995-06-06 1999-05-11 Genetics Institute, Inc. Cartilage induction by bone morphogenetic proteins
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
EP0957943B2 (de) 1997-02-07 2008-11-26 Stryker Corporation Matrixlose osteogene vorrichtungen und implantate und verfahren zu deren verwendung
US6034062A (en) * 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
US7041641B2 (en) 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
US20010016646A1 (en) 1998-03-20 2001-08-23 David C. Rueger Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects
DE69826854T2 (de) 1997-05-05 2006-02-02 Curis, Inc., Cambridge Therapien zur behandlung von akutem nierenversagen
WO1998054572A1 (en) 1997-05-30 1998-12-03 Creative Biomolecules, Inc. Methods for evaluating tissue morphogenesis and activity
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
JP4892131B2 (ja) * 1998-11-13 2012-03-07 ストライカー コーポレイション 癌の症状を緩和する方法
US6727224B1 (en) * 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
EP1210107A2 (de) * 1999-09-08 2002-06-05 Genetics Institute, Inc. Bmp-9 zusammensetzungen und methode zur diferenzierung der cholinergischen neuronen
US6723334B1 (en) * 2000-03-01 2004-04-20 Iowa State University Research Foundation, Inc. Biologically compatible bone cements and orthopedic methods
WO2002077006A1 (en) * 2001-03-23 2002-10-03 Human Genome Sciences, Inc. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US20030082233A1 (en) * 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
US20020114795A1 (en) 2000-12-22 2002-08-22 Thorne Kevin J. Composition and process for bone growth and repair
NZ528320A (en) * 2001-02-23 2005-07-29 Wyeth Corp Composition for inducing cartilaginous tissue formation and maintenance comprising a non-culture expanded CD105+ cells and a BMP
DK1399023T3 (da) * 2001-06-01 2008-08-18 Wyeth Corp Sammensætninger til systemisk indgivelse af sekvenser, der koder for knoglemorfogenese-proteiner
TWI267378B (en) * 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
BR0309877A (pt) 2002-05-03 2005-04-26 Millenium Biologix Inc Peptìdeos estimuladores de tecido conectivo
NZ536478A (en) * 2002-05-17 2008-02-29 Wyeth Corp Injectable or implantable solid, rod- shaped compositions for intraosseous delivery of osteogenic proteins
BRPI0408787A (pt) * 2003-03-27 2006-03-28 Childrens Hosp Medical Center uso de proteìna fgf-18, proteìnas alvo e suas respectivas seqüências de nucleotìdeos codificantes para indução de formação de cartilagem
KR20060133961A (ko) 2003-09-12 2006-12-27 와이어쓰 골형성 단백질 전달용의 주사 가능한 인산칼슘 고형 로드및 페이스트
US8372419B2 (en) 2004-03-10 2013-02-12 Scil Technology Gmbh Coated implants, their manufacturing and use thereof
CA2567405A1 (en) 2004-05-25 2005-12-08 Stryker Corporation Use of morphogenic proteins for treating cartilage defects
EP3059245B1 (de) 2004-07-23 2018-11-07 Acceleron Pharma Inc. Actrii-rezeptor antagonistische antikörper
WO2006081379A1 (en) * 2005-01-26 2006-08-03 Wyeth Use of sfrps as markers of bmp activity
CN101309698A (zh) * 2005-03-30 2008-11-19 惠氏公司 通过施用bmp来刺激毛发生长的方法
KR20180030264A (ko) 2005-11-23 2018-03-21 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EP2035030A2 (de) 2006-05-17 2009-03-18 Stryker Corporation Verwendung löslicher morphogener proteinkomplexe zur behandlung von knorpeldefekten
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US7718616B2 (en) 2006-12-21 2010-05-18 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof
JP5452230B2 (ja) 2006-12-21 2014-03-26 ストライカー コーポレイション 生物学的因子の結晶、高分子ゲルおよび粒子懸濁液を含む持続放出処方物
JP5237970B2 (ja) 2007-02-01 2013-07-17 アクセルロン ファーマ， インコーポレイテッド 乳癌を治療または予防するためのアクチビンＡｃｔＲＩＩａアンタゴニストおよび使用
TW202021980A (zh) 2007-02-02 2020-06-16 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
EP2120999B1 (de) 2007-02-09 2012-08-29 Acceleron Pharma, Inc. Zusammensetzungen enthaltend Activin-ActRIIA-Antagonisten und deren Verwendung bei der Verbeugung oder Behandlung des Multiplen Myeloms
DE102007006843A1 (de) 2007-02-12 2008-08-14 Bioregeneration Gmbh Verfahren und Stützstruktur zum Kultivieren lebender Zellen
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
JP5323832B2 (ja) 2007-08-07 2013-10-23 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー 酸性水溶液中にｇｄｆ−５を含むタンパク質製剤
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
EP2268302B1 (de) 2008-02-13 2014-04-09 Keith Hruska Bmp-7 zur behandlung von neointimaler hyperplasie
AU2009236459B2 (en) 2008-04-14 2013-07-25 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered GDF-5 formulations
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
PL3494986T3 (pl) 2008-08-14 2020-11-16 Acceleron Pharma Inc. Pułapki GDF
WO2010083034A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
JP5819733B2 (ja) 2009-02-12 2015-11-24 ストライカー コーポレイションＳｔｒｙｋｅｒ Ｃｏｒｐｏｒａｔｉｏｎ 障害および疾患に対する全身治療のためのＴＧＦ−βスーパーファミリーメンバー含有タンパク質の末梢投与
AU2010213591B2 (en) 2009-02-12 2013-11-21 Stryker Corporation Compositions and methods for minimally-invasive systemic delivery of proteins including TGF-beta superfamily members
WO2010110974A1 (en) 2009-03-24 2010-09-30 Stryker Corporation Methods and compositions for tissue engineering
EP3345921A1 (de) 2009-06-08 2018-07-11 Acceleron Pharma Inc. Verwendung von anti-actriib antokörper zur erhöhung der zahl thermogener adipozyten
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
US20110224138A1 (en) 2009-09-09 2011-09-15 Julie Krop Methods for treating pain induced by injuries and diseases of an articular joint
CA2773494A1 (en) * 2009-09-09 2011-03-17 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof
CA2774024A1 (en) 2009-09-17 2011-03-24 Stryker Corporation Buffers for controlling the ph of bone morphogenetic proteins
EP3818988A1 (de) * 2009-11-03 2021-05-12 Acceleron Pharma Inc. Verfahren zur behandlung von fettleber
WO2011063018A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
EP2516456A1 (de) 2009-12-22 2012-10-31 Stryker Corporation Bmp-7-varianten mit reduzierter immunogenität
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
WO2012023113A2 (en) 2010-08-20 2012-02-23 Wyeth Llc Designer osteogenic proteins
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
JP2014502260A (ja) 2010-11-08 2014-01-30 アクセルロン ファーマ， インコーポレイテッド Ａｃｔｒｉｉａ結合剤およびその使用
CN103313733A (zh) 2010-11-15 2013-09-18 捷迈整形外科生物材料有限公司 骨空隙填充剂
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
CA2918486C (en) * 2012-07-20 2020-12-08 The Regents Of The University Of California Methods for producing cartilage and bone
US9833481B2 (en) * 2012-09-01 2017-12-05 Ken Muneoka Method for articular cartilage and joint formation
EP3308796B1 (de) 2012-11-02 2021-07-14 Celgene Corporation Activin-actrii-antagonisten und verwendungen zur behandlung von knochen- und anderen erkrankungen
KR20160078375A (ko) * 2013-10-17 2016-07-04 재단법인 제이씨비 공동생물과학연구소 박테리아로부터 발현 및 분리된 생체활성 재조합 bmp-9 단백질인 mb109
AP2017009674A0 (en) 2014-06-13 2017-01-31 Acceleron Pharma Inc Methods and compositions for treating ulcers
GB201412290D0 (en) 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MD4801C1 (ro) 2014-12-03 2022-10-31 Celgene Corporation Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice
AU2016273028B2 (en) 2015-06-05 2019-02-14 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761471A (en) 1980-08-04 1988-08-02 The Regents Of The University Of California Bone morphogenetic protein composition
US4455256A (en) 1981-05-05 1984-06-19 The Regents Of The University Of California Bone morphogenetic protein
US4294753A (en) 1980-08-04 1981-10-13 The Regents Of The University Of California Bone morphogenetic protein process
US4619989A (en) 1981-05-05 1986-10-28 The Regents Of The University Of Cal. Bone morphogenetic protein composition
US4789732A (en) 1980-08-04 1988-12-06 Regents Of The University Of California Bone morphogenetic protein composition
US4434094A (en) 1983-04-12 1984-02-28 Collagen Corporation Partially purified osteogenic factor and process for preparing same from demineralized bone
US4795804A (en) 1983-08-16 1989-01-03 The Regents Of The University Of California Bone morphogenetic agents
US4804744A (en) 1984-01-04 1989-02-14 International Genetic Engineering, Inc. Osteogenic factors
US4608199A (en) 1984-03-20 1986-08-26 Arnold Caplan Bone protein purification process
US4627982A (en) 1984-07-16 1986-12-09 Collagen Corporation Partially purified bone-inducing factor
DE3588058T3 (de) 1984-07-16 2005-04-07 Celtrix Pharmaceuticals, Inc., Palo Alto Knorpel-induzierende Polypeptid-Faktoren aus Knochen
US4843063A (en) 1984-07-16 1989-06-27 Collagen Corporation Polypeptide cartilage-inducing factors found in bone
US4563350A (en) 1984-10-24 1986-01-07 Collagen Corporation Inductive collagen based bone repair preparations
US4886747A (en) 1985-03-22 1989-12-12 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US4681763A (en) 1985-06-11 1987-07-21 University Of Medicine And Dentistry Of New Jersey Composition for stimulating bone growth
US4798885A (en) 1986-02-07 1989-01-17 Genentech, Inc. Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain
US4737578A (en) 1986-02-10 1988-04-12 The Salk Institute For Biological Studies Human inhibin
IL89869A0 (en) 1988-04-06 1989-12-15 Collagen Corp Bone-inducing protein
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5108753A (en) 1988-04-08 1992-04-28 Creative Biomolecules Osteogenic devices
ATE134647T1 (de) 1988-04-08 1996-03-15 Stryker Corp Osteogene vorrichtungen
US4968590A (en) 1988-04-08 1990-11-06 Stryker Corporation Osteogenic proteins and polypeptides
FR2636063B1 (fr) * 1988-09-05 1993-04-30 Centre Nat Rech Scient Composes phenylpyrroliques utiles en tant que medicaments, leur preparation et leur application
US5106626A (en) 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
CA2017466A1 (en) 1989-06-02 1990-12-02 Michael C. Kiefer Bone calcification factor
CA2020729A1 (en) 1989-07-19 1991-01-20 Michael C. Kiefer Bone morphogenetic protein
AU632160B2 (en) 1989-08-21 1992-12-17 Celtrix Pharmaceuticals, Inc. Bone-specific protein
ATE140965T1 (de) 1989-09-06 1996-08-15 Takeda Chemical Industries Ltd Protein, dna und ihre verwendung
WO1991005802A1 (en) 1989-10-17 1991-05-02 Creative Biomolecules, Inc. Osteogenic devices
US5168050A (en) * 1990-05-24 1992-12-01 Genentech, Inc. Mammalian expression of the bone morphogenetic protein-2b using bmp2a/bmp2b fusion
AU8941791A (en) 1990-10-18 1992-05-20 Creative Biomolecules, Inc. Osteogenic protein
EP0643767B1 (de) 1990-10-18 1998-07-22 Stryker Corporation Osteogene peptide
AU652472B2 (en) * 1991-06-25 1994-08-25 Genetics Institute, Llc BMP-9 compositions
CA2116559C (en) 1991-08-30 2005-05-10 Thangavel Kuberasampath Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
ATE192931T1 (de) 1991-08-30 2000-06-15 Creative Biomolecules Inc Morphogen-induzierte modulation von entzündlichen antworten
ES2114073T3 (es) * 1992-09-16 1998-05-16 Creative Biomolecules Inc Regeneracion del higado inducida por morfogenes.
US5902785A (en) * 1995-06-06 1999-05-11 Genetics Institute, Inc. Cartilage induction by bone morphogenetic proteins

Also Published As

Publication number Publication date
JPH10503927A (ja) 1998-04-14
WO1995033830A1 (en) 1995-12-14
JP3706133B2 (ja) 2005-10-12
EP1230930A2 (de) 2002-08-14
DE69528058T2 (de) 2003-05-28
KR100255417B1 (ko) 2000-05-01
EP1230930A3 (de) 2002-11-27
EP0764208B1 (de) 2002-09-04
US6034061A (en) 2000-03-07
AU2817095A (en) 1996-01-04
AU709869B2 (en) 1999-09-09
US6287816B1 (en) 2001-09-11
EP0764208A1 (de) 1997-03-26
DE69528058D1 (de) 2002-10-10

Similar Documents

Publication Publication Date Title
DE69528058D1 (de) Bmp-9 zusammensetzungen
ATE162223T1 (de) Osteoinduktive zusammensetzungen
CA2108770A1 (en) Bmp-9 compositions
DK0536186T3 (da) Knogle- og brusk-dannelsesfremkaldende proteiner
ATE265529T1 (de) Bmp-10 zusammensetzungen
DE60007079D1 (de) Methoden und zusammensetzungen zur heilung und reparatur von gelenkknorpeln
DE60137430D1 (de) Gewebeimplant zur wiederherstellung von knorpelgewebe
FI962350A (fi) BPM-12, BMP-13 sekä niiden jännettä indusoivat koostumukset
DK1690874T3 (da) BMP-12, BMP-13 og sene-inducerende sammensætninger deraf
DE60043075D1 (de) Therapeutische zusammensetzungen und verfahren zur behandlung von periodontitis mit entzündunshemmenden mitteln
DE69133338D1 (de) Bmp-5-derivate
ATE255920T1 (de) Methoden und zusammensetzungen zur heilung und reparatur von gelenkknorpeln
DE69033606D1 (de) Verfahren zur verbesserung der wundheilung und gewebeerneuerung
DE69331479D1 (de) Polyethylenglycol-Hirudin-Konjugate, deren Verfahren zur Herstellung und Verwendung für die Heilung von Thrombosen
DE69433055D1 (de) Zusammensetzung zum heilen von verletztem gewebe, verfahren für ihre herstellung und ihre verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties